insights_auto
Why is GNMSF down 2,39%?
Dive Deeperchevron_right
GNMSF:OTCMKTS
Genmab A/S
US$367,00
arrow_downward
-2,39%(-9,00) 1D
9 ຕ.ລ., 16 ໂມງ 0 ນາທີ 00 ວິນາທີ GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNMSF...
Open
US$367,00
High
US$367,00
Low
US$367,00
Mkt. cap
22,65 ຕື້
Avg. vol.
1,37 ພັນ
Volume
52,00
52-wk high
US$396,97
52-wk low
US$232,50
Beta
0,73
Shares outstanding
62,41 ລ້ານ
No. of employees
3 ພັນ
Open
US$367,00
High
US$367,00
Low
US$367,00
Mkt. cap
22,65 ຕື້
Avg. vol.
1,37 ພັນ
Volume
52,00
52-wk high
US$396,97
52-wk low
US$232,50
Beta
0,73
Shares outstanding
62,41 ລ້ານ
No. of employees
3 ພັນ
News stories
From web sources and news partners
The Globe and Mail
·
1 ມື້ກ່ອນ
Genmab (GMAB) Receives a Buy from Truist Financial
Profile
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US. Wikipedia
About Genmab A/S
CEOJan G. J. van de Winkel
Employees3,12 ພັນ
Founded11 ມິ.ຖ. 1998
Headquarters-
SectorBiotechnology
Websitegenmab.com